DRI Healthcare (TSE:DHT.UN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
DRI Healthcare Trust has invested up to $184 million in a royalty interest in the worldwide sales of sebetralstat, a potential new treatment for hereditary angioedema, and an equity investment in KalVista Pharmaceuticals. This strategic move highlights DRI’s evolving investment strategy and aims to diversify their portfolio with long-term assets. The investment reflects confidence in sebetralstat’s clinical potential and the financial benefits it may offer if approved.
For further insights into TSE:DHT.UN stock, check out TipRanks’ Stock Analysis page.
